Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8842868 | 0.93 | ITGB3 (0.38) | ITGB3ITGA2B | |
| SCHEMBL7325700 | 0.90 | ITGB3 (0.42) | ITGB3ITGA2BALDH1A1CYP1A2MAPT | |
| SCHEMBL7319994 | 0.89 | ITGB3 (0.53) | ITGB3ITGA2B | |
| SCHEMBL7327465 | 0.89 | ITGB3 (0.42) | ITGB3ITGA2B | |
| SCHEMBL7323959 | 0.89 | ITGB3 (0.44) | ITGB3ITGA2B | |
| SCHEMBL7333120 | 0.87 | ITGB3 (0.44) | ITGB3ITGA2BALDH1A1CYP1A2MAPT | |
| SCHEMBL7323534 | 0.86 | ITGB3 (0.45) | ITGB3ITGA2BALDH1A1CYP1A2MAPT | |
| SCHEMBL7329607 | 0.86 | ITGB3 (0.43) | ITGB3ITGA2BALDH1A1CYP1A2MAPT | |
| SCHEMBL7333983 | 0.85 | ITGB3 (0.32) | ITGB3ITGA2B | |
| SCHEMBL7331883 | 0.85 | ITGB3 (0.40) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5663166-A | ANTICOAGULANTS OF 1,4-BENZODIAZEPINE-2,5-DIONE AND 2-BENZOAZEPINE-1,4-DIONE DERIVATIVES; PREVENTS FIBRINOGEN BINDING NECESSARY FOR PLATELET AGGREGATION; SIDE EFFECT REDUCTION, E.G. EXCESSIVE BLEEDING | GENENTECH, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5565449-A | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0610334-B1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII B III A RECEPTOR | GENENTECH INC (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5403836-A | Anticoagulants | GENENTECH, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5250679-A | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor | GENENTECH, INC. (US) | 1993-10-05 | — | — | US | disclosed |
| WO-1993008174-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR | GENENTECH, INC. (US) | 1993-04-29 | — | — | WO | disclosed |